netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Recent Updates - Updated items

All Formulary Amendments

  Records 1 to 30 of 62

Older Oldest

Details
UPD Published from Draft Mode
18/01/2024 09:09:06
(LoweryM )
UPD sitematrix Changed from 0 to
18/01/2024 09:08:58
(LoweryM )
UPD Atezolizumab approved
18/01/2024 09:08:58
(LoweryM )
UPD sitematrix Changed from 0 to
12/01/2024 13:27:43
(DavidS )
UPD isDraft Changed from N to Y
12/01/2024 13:27:43
(DavidS )
UPD FurtherInformation Changed from
12/01/2024 13:27:43
(DavidS )
UPD Atezolizumab Addition of 1875mg SC formulation
12/01/2024 13:27:43
(DavidS )
LDL Link Added : MHRA Drug Safety Update (June 2021): Atezolizumab (Tecentriq▼) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs) : https://www.gov.uk/drug-safety-update/atezolizumab-tecentriqv-and-other-
14/07/2023 13:27:03
(dmcdermott )
LDL Link Added : NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy : https://www.nice.org.uk/guidance/ta525
06/07/2023 12:10:00
(rpaylor )
LDL Link Added : NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy : https://www.nice.org.uk/guidance/ta520
06/07/2023 12:09:41
(rpaylor )
LDL Link Added : NICE TA739: Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable : https://www.nice.org.uk/guidance/ta739
17/11/2022 13:46:44
(DavidS )
LDL Link Added : NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer : https://www.nice.org.uk/guidance/ta639
17/11/2022 13:46:13
(DavidS )
LDL Link Added : NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer : https://www.nice.org.uk/guidance/ta638
17/11/2022 13:45:38
(DavidS )
UPD sitematrix Changed from 0 to
17/11/2022 13:44:35
(DavidS )
UPD FurtherInformation Changed from
17/11/2022 13:44:35
(DavidS )
UPD Atezolizumab NICE TA638, TA639, TA739
17/11/2022 13:44:35
(DavidS )
UPD sitematrix Changed from 0 to
15/11/2022 16:47:58
(DavidS )
UPD FurtherInformation Changed from
15/11/2022 16:47:58
(DavidS )
UPD Atezolizumab NICE TA823
15/11/2022 16:47:58
(DavidS )
LDL Link Added : NICE TA823: Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer : https://www.nice.org.uk/guidance/ta823
15/11/2022 16:47:19
(DavidS )
LDL Link 19549 Deleted : 08.01.05 : https://www.nice.org.uk/guidance/ta739
27/07/2022 14:47:54
(DavidS )
UPD sitematrix Changed from 0 to
27/07/2022 14:47:42
(DavidS )
UPD FurtherInformation Changed from
  • Approved for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults who have had chemotherapy (and targeted treatment if they have an EGFR- or ALK‑positive tumour). 
27/07/2022 14:47:42
(DavidS )
UPD Atezolizumab updated
27/07/2022 14:47:42
(DavidS )
UPD sitematrix Changed from 0 to
27/07/2022 14:47:08
(DavidS )
UPD FurtherInformation Changed from
27/07/2022 14:47:08
(DavidS )
UPD Atezolizumab UPDATED
27/07/2022 14:47:08
(DavidS )
UPD sitematrix Changed from 0 to
27/07/2022 14:44:36
(DavidS )
UPD BlueTeq Changed from N to Y
27/07/2022 14:44:36
(DavidS )
UPD Atezolizumab updated
27/07/2022 14:44:36
(DavidS )

 

 
netFormulary